The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; GlaxoSmithKline; Janssen; Lilly; Merck; Merck Sharp & Dohme; Mirati Therapeutics; Novartis; Pfizer; PharmaMar; Roche; Sanofi; SERVIER; Takeda
Speakers' Bureau - AstraZeneca; Janssen; Merck; Mirati Therapeutics
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst)
EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study of pembrolizumab versus placebo for completely resected early-stage non-small cell lung cancer (NSCLC): Outcomes in subgroups related to surgery, disease burden, and adjuvant chemotherapy use.
 
Mary E.R. O'Brien
Honoraria - Abbvie; Bristol-Myers Squibb; Merck; Merck; Merck Serono
Consulting or Advisory Role - Eisai Europe; ITeos Therapeutics; Merck; Merck; PharmaMar; PharmaMar; Pierre Fabre; Puma Biotechnology
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Luis Paz-Ares
No Relationships to Disclose
 
Nitish Jha
No Relationships to Disclose
 
Urania Dafni
Honoraria - Roche
 
Kersti Oselin
Consulting or Advisory Role - Amgen; AstraZeneca; Janssen; Merck Sharp & Dohme; Roche; Takeda
Research Funding - Pfizer (Inst); Takeda (Inst)
 
Libor Havel
No Relationships to Disclose
 
Emilio Esteban
No Relationships to Disclose
 
Dolores Isla
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; GlaxoSmithKline; Janssen; Merck Sharp & Dohme; Pfizer; Roche; Sanofi; Takeda
Speakers' Bureau - Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Merck Sharp & Dohme; Pfizer; Roche; Takeda
Research Funding - GlaxoSmithKline (Inst)
 
Alex Martinez-Marti
Consulting or Advisory Role - AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Merck Sharp & Dohme; MSD Oncology; Pfizer; Roche
Speakers' Bureau - AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Merck Sharp & Dohme; Pfizer; Roche
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Merck Sharp & Dohme; Pfizer; Roche
 
Martin Faehling
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Merck Sharp & Dohme; Roche
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Roche; Sanofi
Research Funding - AstraZeneca (Inst); Merck Sharp & Dohme (Inst); Roche (Inst)
 
Masahiro Tsuboi
Honoraria - AstraZeneca Japan; Bristol-Myers Squibb Japan; Chugai Pharma; Johnson & Johnson; Lilly Japan; Medtronic; MSD K.K; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Teijin Pharma
Consulting or Advisory Role - AstraZeneca Japan; Chugai Pharma; Lilly Japan; MSD; Novartis
Research Funding - AstraZeneca Japan (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb KK (Inst); Merck (Inst); Ono Pharmaceutical (Inst)
 
Jong-Seok Lee
No Relationships to Disclose
 
Kazuhiko Nakagawa
Honoraria - 3H Clinical Trial; Amgen; AstraZeneca Japan; Bayer Yakuhin; CareNet; Chugai Pharma; CMIC; CMIC Co., Ltd.; Japan Clinical Research Operations; Kyowa Kirin Co., Ltd.; Kyowa Kirin Co., Ltd.; Life Technologies; Lilly Japan; Medical Mobile Communications; Medical Review Co., Ltd.; Merck; MSD K.K; Neo Communication; Nikkei Business Publications, Inc; Nippon Boehringer Ingelheim; Nippon Boehringer Ingelheim; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Taiyo Pharma; Takeda; YODOSHA
Consulting or Advisory Role - Lilly Japan; Ono Pharmaceutical
Research Funding - Amgen (Inst); AstraZeneca Japan (Inst); Bayer Yakuhin (Inst); Bristol-Myers Squibb K.K. (Inst); Chugai Pharma (Inst); Covance (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EPS Holdings (Inst); EPS Holdings (Inst); EPS International (Inst); GlaxoSmithKline K.K. (Inst); IQvia (Inst); Janssen (Inst); Japan Clinical Research Operations (Inst); Kissei Pharmaceutical (Inst); Lilly Japan (Inst); Mebix (Inst); Medical Reserch Support (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); MSD K.K (Inst); Nippon Boehringer Ingelheim (Inst); Nippon Kayaku (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); PAREXEL International Corp. (Inst); PPD-SNBL (Inst); PRA HEALTHSCIENCES (Inst); Sanofi (Inst); SRL Diagnostics (Inst); SymBio Pharmaceuticals (Inst); Syneos Health (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
Patents, Royalties, Other Intellectual Property - Daiichi Sankyo Co., Ltd. (Inst)
 
Jing Yang
Employment - Merck Sharp & Dohme
 
Steven M. Keller
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
 
Murielle Mauer
No Relationships to Disclose
 
Sandrine Marreaud
No Relationships to Disclose
 
Rolf A. Stahel
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; GlaxoSmithKline; Merck Sharp & Dohme; Roche; Sandoz; Seagen; Takeda
Speakers' Bureau - Amgen; AstraZeneca; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; GlaxoSmithKline; Merck Sharp & Dohme; Novartis; Roche
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo (Inst); Ipsen (Inst); Janssen (Inst); Merck Sharp & Dohme (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche (Inst)
 
Benjamin Besse
Research Funding - 4D Pharma (Inst); Abbvie (Inst); Amgen (Inst); Aptitude Health (Inst); AstraZeneca (Inst); BeiGene (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); cergentis (Inst); Chugai Pharma (Inst); Cristal Therapeutics (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Genzyme (Inst); GlaxoSmithKline (Inst); Inivata (Inst); Ipsen (Inst); Janssen Oncology (Inst); Lilly (Inst); Onxeo (Inst); OSE Immunotherapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst); Takeda (Inst); Tolero Pharmaceuticals (Inst); Turning Point Therapeutics (Inst)
 
Solange Peters
Honoraria - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Ecancer (Inst); Ecancer (Inst); Illumina (Inst); Imedex (Inst); medscape (Inst); MSD (Inst); Novartis (Inst); PER (Inst); Pfizer (Inst); Prime Oncology (Inst); Research to Practice (Inst); RMEI Medical Education (Inst); Roche (Inst); Takeda (Inst)
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Biocartis (Inst); Bioinvent (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); Foundation Medicine (Inst); Illumina (Inst); Incyte (Inst); Janssen (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Phosplatin Therapeutics (Inst); Regeneron (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Takeda (Inst); Vaccibody (Inst)
Research Funding - Amgen (Inst); AstraZeneca (Inst); Biodesix (Inst); BMS (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Illumina (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Phosplatin Therapeutics (Inst); roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Incyte; MSD; Roche; Sanofi
(OPTIONAL) Uncompensated Relationships - Annals of Oncology (I); ESMO; European Thoracic Oncology Platform (ETOP); Journal of Thoracic Oncology